Canada markets closed

Novavax, Inc. (NVAX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
193.36-9.88 (-4.86%)
At close: 4:00PM EDT
188.60 -4.76 (-2.46%)
After hours: 07:59PM EDT

Novavax, Inc.

21 Firstfield Road
Gaithersburg, MD 20878
United States
240 268 2000
http://www.novavax.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees792

Key Executives

NameTitlePayExercisedYear Born
Mr. Stanley Charles ErckPres, CEO & Director1.26M8.04M1948
Mr. John Joseph TrizzinoExec. VP, Interim CFO, Chief Bus. & Commercial Officer & Treasurer676.83k7.28M1960
Mr. John A. Herrmann IIIExec. VP, Chief Legal Officer & Corp. Sec.655.95k7.07M1966
Dr. Gregory M. GlennPres of R&D857.42k9.14M1954
Mr. Richard P. CrowleyExec. VP & COON/AN/A1957
Dr. Gale E. SmithSr. VP of Discovery & Pre-Clinical Research and Chief ScientistN/AN/A1950
Mr. Biegie LeeSr. VP & Chief Information OfficerN/AN/AN/A
Ms. Silvia Taylor M.B.A., MBASr. VP of Investor Relations & Corp. AffairsN/AN/AN/A
Mr. Troy Morgan Esq.Sr. VP & Chief Compliance OfficerN/AN/A1971
Ms. Erika S. TrahanAssociate Director of Investor & PRN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Novavax, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 5; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.